InvestorsHub Logo
Followers 73
Posts 6214
Boards Moderated 0
Alias Born 05/01/2011

Re: rfj1862 post# 155346

Wednesday, 11/07/2018 4:06:31 PM

Wednesday, November 07, 2018 4:06:31 PM

Post# of 426274

While Vascepa may very well have benefits beyond CV, it would likely take a very large, expensive, and long trial to prove it.


Interesting that you say that, because they just completed a very large, expensive, and long trial that has Total Mortality as a secondary endpoint.

Hopefully all the prior SEs are stat sig so we can have that data point available for label consideration.

“The trick is in what one emphasizes. We either make ourselves miserable, or we make ourselves happy. The amount of work is the same.” Carlos Castaneda

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News